alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 41 studies by Dartigues JF (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Dietary patterns and risk of dementia: the Three-City cohort study

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Neurology 2007-11-01

Frequent consumption of fruits and vegetables, fish, and omega-3 rich oils may decrease the risk of dementia and Alzheimer disease, especially among ApoE epsilon 4 noncarriers. 4 key findings →

Design: cohort study Participants: 8,085 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia

✓ Peer-reviewed alzhub usefulness score 72 out of 100. JAMA 2018-08-01

In this cohort of older adults, increased numbers of optimal cardiovascular health metrics and a higher cardiovascular health score were associated with a lower risk of dementia and lower rates of cognitive decline. 5 key findings →

Design: cohort study Participants: 6,626 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms

✓ Peer-reviewed alzhub usefulness score 68 out of 100. CNS drugs 2015-02-01

In the seven longitudinal studies assessing the effect of antihypertensive medication on cognitive impairment or cognitive decline, antihypertensive drugs appeared to be beneficial. 4 key findings →

Design: systematic review Participants: 1,346,176 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Progression of mild cognitive impairment to dementia due to AD in clinical settings

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurology 2015-07-01

Under circumstances emulating routine clinical practice, the positive predictive value of an MCI diagnosis is in line with previous clinical studies and the external validity of the concept is strengthened. 4 key findings →

Design: cohort study Participants: 446,439 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. PLoS medicine 2017-03-28

Fasting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC]) were studied as continuous variables, and results are reported per SD increase of each lipid fraction. 5 key findings →

Design: cohort study Participants: 9,294 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or their Combinaison on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. The journal of nutrition, health & aging 2018-01-01

This population-based study in community-dwellers aged 70 years or over suggested that multidomain intervention and n3 PUFA supplementation have not significant effects on cognitive function change in frail older adults with memory complaints. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Prodromal Alzheimer's disease: successive emergence of the clinical symptoms

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Annals of neurology 2008-11-01

This approach, describing the 14 years preceding dementia, provides a clear illustration of the particularly long and progressive prodromal phase of AD, and shows the successive emergence of cognitive deficits, depressive symptoms, and functional impairment during this phase. 2 key findings →

Design: case-control study Participants: 350 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of the American Geriatrics Society 2007-11-20

This study is the first to show that, 10 years before the clinical diagnosis of dementia, subjects who later developed dementia performed worse in complex activities of daily living, which may constitute an early marker of the disease. 2 key findings →

Design: prospective cohort Participants: 104 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of smoking on global cognitive function in nondemented elderly

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neurology 2004-03-01

Contrary to early case-control studies that suggested smoking protects against Alzheimer disease (AD), recent prospective studies have shown that elderly who smoke may be at increased risk for dementia. 4 key findings →

Design: case-control study Participants: 17,610 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Restriction in complex activities of daily living in MCI: impact on outcome

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2006-08-01

Inclusion of instrumental activities of daily living restriction in the criteria of mild cognitive impairment improves the prediction of dementia and the stability of this status over time. 3 key findings →

Design: cross-sectional Participants: 1,517 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Neurology 2005-05-01

This observational study provides further evidence that lipid-lowering agents are associated with decreased risk of dementia, whereas hyperlipidemia is associated with increased odds for non-Alzheimer-disease-type dementia. 5 key findings →

Participants: 9,294 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journal of prevention of Alzheimer's disease 2014-06-01

AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. 1 key finding →

Participants: 1,680 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Diabetes care 2008-10-22

The observed relation between high triglycerides, diabetes, and vascular dementia emphasizes the need for detection and treatment of vascular risk factors in older individuals in order to prevent the likelihood of clinical dementia. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration

✓ Peer-reviewed alzhub usefulness score 58 out of 100. American journal of epidemiology 1996-10-01

Although many studies have found a cross-sectional relation between depression and dementia or depressive symptomatology and cognitive functioning, the direction of the association is still unknown. 4 key findings →

Design: cohort study Participants: 1,600 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed